The impact of 1,25(OH)2D3 and its structural analogs on gene expression in cancer cells - A microarray approach

Anticancer Research

Volumn 29, Issue 9, 2009, Pages 3471-3483

  Kriebitzsch, Carsten ^a   Verlinden, Lieve ^a   Eelen, Guy ^a   Biauw, Keng Tan ^a   Van Camp, Mark ^a   Bouillon, Roger ^a   Verstuyf, Annemieke ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b LEGENDO   (Belgium)

Author keywords

1,25(OH)2D3; Analog; Cancer; Microarray; Review

Indexed keywords

CALCITRIOL; CATHELICIDIN; CCAAT ENHANCER BINDING PROTEIN DELTA; CYCLINE; EXPORTIN 1; FATTY ACID SYNTHASE; INITIATION FACTOR; KARYOPHERIN; OXYGENASE; POLYPEPTIDE ANTIBIOTIC AGENT; RO 3582; SOMATOMEDIN BINDING PROTEIN 3; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE;

APOPTOSIS; BONE METABOLISM; BREAST CANCER; CALCIUM HOMEOSTASIS; CANCER CELL; CELL ADHESION; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; COLORECTAL CANCER; CONFERENCE PAPER; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNITY; LEUKEMIA; MICROARRAY ANALYSIS; OVARY CANCER; OXIDATIVE STRESS; PHOSPHATE METABOLISM; PLEIOTROPY; PRIORITY JOURNAL; PROSTAGLANDIN METABOLISM; PROSTATE CANCER; SQUAMOUS CELL CARCINOMA; STEROID METABOLISM;

CALCITRIOL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 68549107747     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (110)

1. Dusso AS, Brown AJ and Slatopolsky E: Vitamin D. Am J Physiol Renal Physiol 289: F8-28, 2005.
2. 3. Clin Endocrinol 13: 267-272, 1980. (Pubitemid 10003406)
3. 3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. Endocrinology 108: 1083-1086, 1981.
4. 3. Proc Natl Acad Sci USA 78: 4990-4994, 1981. (Pubitemid 12225607)
5. 3 in HL60 cells. Cancer Res 56: 264-267, 1996.
6. 3 on the cell cycle genes, cyclin D1, p21 and p27 in MCF-7 cells. Mol Cell Endocrinol 142: 57-65, 1998. (Pubitemid 28438279)
7. Jensen SS, Madsen MW, Lukas J, Binderup L and Bartek J: Inhibitory effects of 1alpha,25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery. Mol Endocrinol 15: 1370-1380, 2001.
8. Li P, Li C, Zhao X, Zhang X, Nicosia SV and Bai W: p27(Kip1) stabilization and G(1) arrest by 1,25-dihydroxyvitamin D(3) in ovarian cancer cells mediated through down-regulation of cyclin E/cyclin-dependent kinase 2 and Skp1-Cullin-F-box protein/Skp2 ubiquitin ligase. J Biol Chem 279: 25260-25267, 2004. (Pubitemid 38756778)
9. Deeb KK, Trump DL and Johnson CS: Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 7: 684-700, 2007.
10. Kulesh DA, Clive DR, Zarlenga DS and Greene JJ: Identification of interferon-modulated proliferation-related cDNA sequences. Proc Natl Acad Sci USA 84: 84538457, 1987.
11. Schena M, Shalon D, Davis RW and Brown PO: Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270: 467-470, 1995.
12. 3 modulated gene expression patterns in human primary normal and cancer prostate cells. J Cell Biochem 93: 271-285, 2004. (Pubitemid 44264205)
13. 3 in androgen-responsive prostate cancer LNCaP cells. Cancer Res 65: 4762-4768, 2005. (Pubitemid 40740813)
14. 3 receptor signalling in prostate cancer cells. Oncogene 23: 6712-6725, 2004. (Pubitemid 39280003)
15. Krishnan AV, Shinghal R, Raghavachari N, Brooks JD, Peehl DM and Feldman D: Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays. Prostate 59: 243-251, 2004. (Pubitemid 38509756)
16. Moreno J, Krishnan AV, Peehl DM and Feldman D: Mechanisms of vitamin D-mediated growth inhibition in prostate cancer cells: inhibition of the prostaglandin pathway. Anticancer Res 26: 2525-2530, 2006. (Pubitemid 44155531)
17. 3 in primary cultures of human prostatic epithelial cells revealed by cDNA microarray analysis. J Steroid Biochem Mol Biol 92: 131-141, 2004. (Pubitemid 39535854)
18. 3 and androgen control of prostate cancer LNCaP cell growth. Biochem Biophys Res Commun 319: 358-368, 2004. (Pubitemid 38725954)
19. 3 suppresses the androgen-stimulated growth of mouse mammary carcinoma SC-3 cells by transcriptional repression of fibroblast growth factor 8. J Cell Physiol 207: 793-799, 2006. (Pubitemid 43668244)
20. Lyakhovich A, Aksenov N, Pennanen P, Miettinen S, Ahonen MH, Syvala H, Ylikomi T and Tuohimaa P: Vitamin D induced up-regulation of keratinocyte growth factor (FGF-7/KGF) in MCF-7 human breast cancer cells. Biochem Biophys Res Commun 273: 675-680, 2000. (Pubitemid 30599043)
21. Swami S, Raghavachari N, Muller UR, Bao YP and Feldman D: Vitamin D growth inhibition of breast cancer cells: gene expression patterns assessed by cDNA microarray. Breast Cancer Res Treat 80: 49-62, 2003. (Pubitemid 36851284)
22. Song JH, Kim JM, Kim SH, Kim HJ, Lee JJ, Sung MH, Hwang SY and Kim TS: Comparison of the gene expression profiles of monocytic versus granulocytic lineages of HL-60 leukemia cell differentiation by DNA microarray analysis. Life Sci 73: 1705-1719, 2003.
23. 3 in human promyelocytic leukemia HL-60 cells. Biomed Res 27: 99-109, 2006. (Pubitemid 44110971)
24. Savli H, Aalto Y, Nagy B, Knuutila S and Pakkala S: Gene expression analysis of 1,25(OH)(2)D-3-dependent differentiation of HL-60 cells: a cDNA array study. Br J Haematol 118: 1065-1070, 2002.
25. Wood RJ, Tchack L, Angelo G, Pratt RE and Sonna LA: DNA microarray analysis of vitamin D-induced gene expression in a human colon carcinoma cell line. Physiol Genomics 17: 122-129, 2004. (Pubitemid 38924158)
26. 3 in human colon cancer cells. Cancer Res 63: 7799-7806, 2003. (Pubitemid 37466712)
27. 3 revealed by microarray analysis. J Biol Chem 280: 35458-35468, 2005. (Pubitemid 41532736)
28. 3 and its analog EB1089 under growth-inhibitory conditions in squamous carcinoma cells. Mol Endocrinol 15: 1127-1139, 2001. (Pubitemid 32614067)
29. Lin R, Nagai Y, Sladek R, Bastien Y, Ho J, Petrecca K, Sotiropoulou G, Diamandis EP, Hudson TJ and White JH: Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D-3 analog EB1089 signaling on cell proliferation, differentiation, and immune system regulation. Mol Endocrinol 16: 1243-1256, 2002. (Pubitemid 34621073)
30. Chen TC and Holick MF: Vitamin D and prostate cancer prevention and treatment. Trends Endocrinol Metab 14: 423-430, 2003.
31. Feldman D, Skowronski RJ and Peehl DM: Vitamin D and prostate cancer. Adv Exp Med Biol 375: 53-63, 1995.
32. Krill D, Stoner J, Konety BR, Becich MJ and Getzenberg RH: Differential effects of vitamin D on normal human prostate epithelial and stromal cells in primary culture. Urology 54: 171-177, 1999. (Pubitemid 29323353)
33. 3 suppresses interleukin8-mediated prostate cancer cell angiogenesis. Carcinogenesis 27: 1883-1893, 2006.
34. Moreno J, Krishnan AV and Feldman D: Molecular mechanisms mediating the anti-proliferative effects of vitamin D in prostate cancer. J Steroid Biochem Mol Biol 97: 31-36, 2005. (Pubitemid 41546211)
35. 3 in prostate cancer cells. J Steroid Biochem Mol Biol 85: 1-8, 2003. (Pubitemid 36700412)
36. Firth SM and Baxter RC: Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 23: 824-854, 2002. (Pubitemid 35454590)
37. Yu H and Rohan T: Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92: 1472-1489, 2000. (Pubitemid 30757421)
38. Krishnan AV, Peehl DM and Feldman D: Inhibition of prostate cancer growth by vitamin D: Regulation of target gene expression. J Cell Biochem 88: 363-371, 2003. (Pubitemid 36119910)
39. Fujita H, Koshida K, Keller ET, Takahashi Y, Yoshimito T, Namiki M and Mizokami A: Cyclooxygenase-2 promotes prostate cancer progression. Prostate 53: 232-240, 2002. (Pubitemid 35266184)
40. Yan M, Rerko RM, Platzer P, Dawson D, Willis J, Tong M, Lawrence E, Lutterbaugh J, Lu S, Willson JK, Luo G, Hensold J, Tai HH, Wilson K and Markowitz SD: 15Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers. Proc Natl Acad Sci USA 101: 17468-17473, 2004. (Pubitemid 39657428)
41. +-linked 15hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer. Carcinogenesis 26: 65-72, 2005. (Pubitemid 40207700)
42. Dunn BK, Wickerham L and Ford LG: Prevention of hormone-related cancers: Breast cancer. J Clin Oncol 23: 357-367, 2005. (Pubitemid 46209965)
43. Boyle BJ, Zhao XY, Cohen P and Feldman D: Insulin-like growth factor-binding protein-3 mediates 1 alpha,25-dihydroxyvitamin d(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. J Urol 165: 1319-1324, 2001. (Pubitemid 32210283)
44. Lee HJ, Liu H, Goodman C, Ji Y, Maehr H, Uskokovic M, Notterman D, Reiss M and Suh N: Gene expression profiling changes induced by a novel Gemini vitamin D derivative during the progression of breast cancer. Biochem Pharmacol 72: 332-343, 2006. (Pubitemid 43975086)
45. Moses HL, Arteaga CL, Alexandrow MG, Dagnino L, Kawabata M, Pierce DF, Jr. and Serra R: TGF beta regulation of cell proliferation. Princess Takamatsu Symp 24: 250-263, 1994.
46. Towsend K, Trevino V, Falciani F, Stewart PM, Hewison M and Campbell MJ: Identification of VDR-responsive gene signatures in breast cancer cells. Oncology 71: 111-123, 2006.
47. Wakefield LM, Piek E and Bottinger EP: TGF-beta signaling in mammary gland development and tumorigenesis. J Mammary Gland Biol Neoplasia 6: 67-82, 2001. (Pubitemid 33640647)
48. Marsh SK, Bansal GS, Zammit C, Barnard R, Coope R, Roberts-Clarke D, Gomm JJ, Coombes RC and Johnston CL: Increased expression of fibroblast growth factor 8 in human breast cancer. Oncogene 18: 1053-1060, 1999. (Pubitemid 29086282)
49. Stollenwerk MM, Lindholm MW, Porn-Ares MI, Larsson A, Nilsson J and Ares MP: Very low-density lipoprotein induces interleukin-1beta expression in macrophages. Biochem Biophys Res Commun 335: 603-608, 2005. (Pubitemid 41140264)
50. Karki P, Dahal GR and Park IS: Both dimerization and interdomain processing are essential for caspase-4 activation. Biochem Biophys Res Commun 356: 1056-1061, 2007. (Pubitemid 46546646)
51. Fujikawa K, Shiraki K, Sugimoto K, Ito T, Yamanaka T, Takase K and Nakano T: Reduced expression of ICE/caspase1 and CPP32/caspase3 in human hepatocellular carcinoma. Anticancer Res 20: 1927-1932, 2000.
52. Arner ES and Holmgren A: The thioredoxin system in cancer. Semin Cancer Biol 16: 420-426, 2006.
53. Salehi F, Dunfield L, Phillips KP, Krewski D and Vanderhyden BC: Risk factors for ovarian cancer: an overview with emphasis on hormonal factors. J Toxicol Environ Health B Crit Rev 11: 301-321, 2008.
54. Zhang X, Jiang F, Li P, Li C, Ma Q, Nicosia SV and Bai W: Growth suppression of ovarian cancer xenografts in nude mice by vitamin D analogue EB1089. Clin Cancer Res 11: 323-328, 2005. (Pubitemid 40075811)
55. So J, Navari J, Wang FQ and Fishman DA: Lysophosphatidic acid enhances epithelial ovarian carcinoma invasion through the increased expression of interleukin-8. Gynecol Oncol 95: 314-322, 2004. (Pubitemid 39445866)
56. Raghuwanshi SK, Nasser MW, Chen X, Strieter RM and Richardson RM: Depletion of beta-arrestin-2 promotes tumor growth and angiogenesis in a murine model of lung cancer. J Immunol 180: 5699-5706, 2008.
57. Hu YL, Tee MK, Goetzl EJ, Auersperg N, Mills GB, Ferrara N and Jaffe RB: Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J Natl Cancer Inst 93: 762-768, 2001. (Pubitemid 32514799)
58. Palmer HG, Gonzalez-Sancho JM, Espada J, Berciano MT, Puig I, Baulida J, Quintanilla M, Cano A, de Herreros AG, Lafarga M and Munoz A: Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J Cell Biol 154: 369-387, 2001. (Pubitemid 34286147)
59. Karin M and Gallagher E: From JNK to pay dirt: jun kinases, their biochemistry, physiology and clinical importance. IUBMB Life 57: 283-295, 2005. (Pubitemid 40904256)
60. Shaulian E and Karin M: AP-1 as a regulator of cell life and death. Nat Cell Biol 4: E131-136, 2002. (Pubitemid 34521026)
61. Shaulian E and Karin M: AP-1 in cell proliferation and survival. Oncogene 20: 2390-2400, 2001.
62. Karin M: The regulation of AP-1 activity by mitogen-activated protein kinases. Philos Trans R Soc Lond B Biol Sci 351: 127-134, 1996.
63. 3 in the C2C12 muscle cell line. J Cell Biochem 97: 698-708, 2006.
64. 3 stimulates activator protein 1 DNA-binding activity by a phosphatidylinositol 3-kinase/Ras/MEK/extracellular signal regulated kinase 1/2 and c-Jun N-terminal kinase 1-dependent increase in c-Fos, Fral, and c-Jun expression in human keratinocytes. J Invest Dermatol 120: 561-570, 2003. (Pubitemid 36343998)
65. Qi X, Pramanik R, Wang J, Schultz RM, Maitra RK, Han J, DeLuca HF and Chen G: The p38 and JNK pathways cooperate to trans-activate vitamin D receptor via cJun/AP-1 and sensitize human breast cancer cells to vitamin D(3)-induced growth inhibition. J Biol Chem 277: 25884-25892, 2002. (Pubitemid 34967068)
66. Ward Y and Kelly K: Gem protein signaling and regulation. Methods Enzymol 407: 468-483, 2006.
67. 2+ channel expression at the cell surface by the small G-protein kir/Gem. Nature 411: 701-706, 2001. (Pubitemid 32531676)
68. Meyers MB, Schneider KA, Spengler BA, Chang TD and Biedler JL: Sorcin (V19), a soluble acidic calcium-binding protein overproduced in multidrug-resistant cells identification of the protein by anti-sorcin antibody. Biochem Pharmacol 36: 2373-2380, 1987.
69. Wissenbach U and Niemeyer BA: Trpv6. In: Handb Exp Pharmacol. Flockerzi V and Nilius B (eds.). Springer Berlin Heidelberg, pp. 221-234, 2007.
70. 3 in intestinal cells. Mol Endocrinol 20: 1447-1461, 2006. (Pubitemid 43801243)
71. 3 on genes involved in calcium homeostasis. J Bone Miner Res 22(Suppl 2): V16-19, 2007.
72. Emami N and Diamandis EP: Human tissue kallikreins: a road under construction. Clin Chim Acta 381: 78-84, 2007. (Pubitemid 46719134)
73. Borgono CA, Michael IP and Diamandis EP: Human tissue kallikreins: physiologic roles and applications in cancer. Mol Cancer Res 2: 257-280, 2004. (Pubitemid 39031076)
74. Anisowicz A, Sotiropoulou G, Stenman G, Mok SC and Sager R: A novel protease homolog differentially expressed in breast and ovarian cancer. Mol Med 2: 624-636, 1996. (Pubitemid 26353111)
75. Yousef GM, Borgono CA, White NM, Robb JD, Michael IP, Oikonomopoulou K, Khan S and Diamandis EP: In silico analysis of the human kallikrein gene 6. Tumour Biol 25: 282-289, 2004.
76. 3 regulates genes responsible for detoxification in intestine. Toxicol Appl Pharmacol 218: 37-44, 2007.
77. 3 analogue EB1089 in head and neck squamous cell carcinoma. J Natl Cancer Inst 93: 745-753, 2001. (Pubitemid 32514797)
78. Akutsu N, Bastien Y, Lin R, Mader S and White JH: Amphiregulin is a vitamin D-3 target gene in squamous cell and breast carcinoma. Biochem Biophys Res Comm 281: 1051-1056, 2001. (Pubitemid 32917840)
79. Rubnitz JE, Gibson B and Smith FO: Acute myeloid leukemia. Pediatr Clin North Am 55: 21-51, ix, 2008.
80. Wang X, Rao J and Studzinski GP: Inhibition of p38 MAP kinase activity up-regulates multiple MAP kinase pathways and potentiates 1,25-dihydroxyvitamin D(3)-induced differentiation of human leukemia HL60 cells. Exp Cell Res 258: 425-437, 2000. (Pubitemid 30483521)
81. Gallagher R, Collins S, Trujillo J, McCredie K, Ahearn M, Tsai S, Metzgar R, Aulakh G, Ting R, Ruscetti F and Gallo R: Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. Blood 54: 713-733, 1979. (Pubitemid 10227870)
82. 3 and its fluorinated analogues. Cancer Res 44: 5624-5628, 1984. (Pubitemid 15183567)
83. 3, all trans retinoic acid, rTGF-beta2 and their combinations. J Steroid Biochem Mol Biol 60: 87-97, 1997. (Pubitemid 27216428)
84. 3, precedes down-regulation of the c-myc gene. J Cell Physiol 128: 171-179, 1986.
85. Studzinski GP, Bhandal AK and Brelvi ZS: A system for monocytic differentiation of leukemic cells HL 60 by a short exposure to 1,25-dihydroxycholecalciferol. Proc Soc Exp Biol Med 179: 288-295, 1985.
86. Ishii Y, Kasukabe T and Honma Y: Immediate up-regulation of the calcium-binding protein S-100P and its involvement in the cytokinin-induced differentiation of human myeloid leukemia cells. Biochim Biophys Acta 1745: 156-165, 2005. (Pubitemid 41207889)
87. 3 suppresses exportin expression in human promyelocytic leukemia HL-60 cells. Biomed Res 27: 89-92, 2006. (Pubitemid 43757421)
88. Delaunay J, Lecomte N, Bourcier S, Qi J, Gadhoum Z, Durand L, Chomienne C, Robert-Lezenes J and Smadja-Joffe F: Contribution of GM-CSF and IL-8 to the CD44-induced differentiation of acute monoblastic leukemia. Leukemia 22: 873-876, 2008. (Pubitemid 351552645)
89. Bagby GC Jr: Interleukin-1 and hematopoiesis. Blood Rev 3: 152-161, 1989.
90. 3 and 12-O-tetradecanoyl phorbol-13-acetate. Leuk Res 29: 1141-1151, 2005. (Pubitemid 41169231)
91. Kuwayama A, Kuruto R, Horie N, Takeishi K and Nozawa R: Appearance of nuclear factors that interact with genes for myeloid calcium-binding proteins (MRP-8 and MRP-14) in differentiated HL-60 cells. Blood 81: 3116-3121, 1993. (Pubitemid 23162132)
92. Court EL, Smith MA, Avent ND, Hancock JT, Morgan LM, Gray AG and Smith JG: DNA microarray screening of differential gene expression in bone marrow samples from AML, non-AML patients and AML cell lines. Leuk Res 28: 743-753, 2004.
93. Bommer UA, Lutsch G, Stahl J and Bielka H: Eukaryotic initiation factors eIF-2 and eIF-3: interactions, structure and localization in ribosomal initiation complexes. Biochimie 73: 1007-1019, 1991.
94. Kutay U, Lipowsky G, Izaurralde E, Bischoff FR, Schwarzmaier P, Hartmann E and Gorlich D: Identification of a tRNA-specific nuclear export receptor. Mol Cell 1: 359369, 1998. (Pubitemid 128378884)
95. Watanabe M, Fukuda M, Yoshida M, Yanagida M and Nishida E: Involvement of CRM1, a nuclear export receptor, in mRNA export in mammalian cells and fission yeast. Genes Cells 4: 291-297, 1999. (Pubitemid 29287631)
96. Bohnsack MT, Regener K, Schwappach B, Saffrich R, Paraskeva E, Hartmann E and Gorlich D: Exp5 exports eEF1A via tRNA from nuclei and synergizes with other transport pathways to confine translation to the cytoplasm. Embo J 21: 6205-6215, 2002. (Pubitemid 35415337)
97. Brownawell AM and Macara IG: Exportin-5, a novel karyopherin, mediates nuclear export of double-stranded RNA binding proteins. J Cell Biol 156: 53-64, 2002.
98. Stuven T, Hartmann E and Gorlich D: Exportin 6: a novel nuclear export receptor that is specific for profilin.actin complexes. Embo J 22: 5928-5940, 2003. (Pubitemid 37408828)
99. Koster M, Lykke-Andersen S, Elnakady YA, Gerth K, Washausen P, Hofle G, Sasse F, Kjems J and Hauser H: Ratjadones inhibit nuclear export by blocking CRM1/exportin 1. Exp Cell Res 286: 321-331, 2003. (Pubitemid 36566444)
100. Yoshida M, Nishikawa M, Nishi K, Abe K, Horinouchi S and Beppu T: Effects of leptomycin B on the cell cycle of fibroblasts and fission yeast cells. Exp Cell Res 187: 150-156, 1990. (Pubitemid 20069610)
101. 3 suppresses gene expression of eukaryotic translation initiation factor 2 in human promyelocytic leukemia HL-60 cells. Cell Struct Funct 30: 1-6, 2005. (Pubitemid 41007761)
102. 1 switch gene 2 is a novel PPAR target gene. Biochem J 392: 313-324, 2005. (Pubitemid 41796520)
103. Kitareewan S, Blumen S, Sekula D, Bissonnette RP, Lamph WW, Cui Q, Gallagher R and Dmitrovsky E: G0S2 is an all-trans-retinoic acid target gene. Int J Oncol 33: 397-404, 2008.
104. Waf1/Cip1 with PCNA. Oncogene 11: 1931-1937, 1995.
105. Takekawa M and Saito H: A family of stress-inducible GADD45-like proteins mediate activation of the stress-responsive MTK1/MEKK4 MAPKKK. Cell 95: 521-530, 1998. (Pubitemid 28533308)
106. 3 in ovarian cancer cells mediated through the induction of GADD45 via an exonic enhancer. J Biol Chem 278: 48030-48040, 2003. (Pubitemid 37523253)
107. Chen A, Davis BH, Sitrin MD, Brasitus TA and Bissonnette M: Transforming growth factor-beta 1 signaling contributes to Caco-2 cell growth inhibition induced by 1,25(OH)(2)D(3). Am J Physiol Gastrointest Liver Physiol 253: G864-874, 2002.
108. 3 induced growth inhibition of PC-3 prostate cancer cells requires an active transforming growth factor beta signaling pathway. Prostate 59: 282-291, 2004. (Pubitemid 38509761)
109. 3 in various tissues. J Steroid Biochem Mol Biol 103: 552-557, 2007. (Pubitemid 46420532)
110. Gombart AF, Borregaard N and Koeffler HP: Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J 19: 1067-1077, 2005. (Pubitemid 40946432)